Patents by Inventor Jingfang Ju

Jingfang Ju has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220226815
    Abstract: The present disclosure is directed to a microwell array comprising a plurality of wells of micro-size dimensions created on porous materials. The device can be used in various cell and tissue analytical activities, and can be formed using an etching, laminating or imprinting processes.
    Type: Application
    Filed: May 8, 2020
    Publication date: July 21, 2022
    Applicant: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Eric BROUZES, Jin Zhu YU, Anu Priya Bharathi RAJAN, Jingfang JU, Gabor BALAZSI
  • Publication number: 20220145304
    Abstract: The present disclosure provides modified microRNA nucleic acid compositions that have one or more cytosine and/or uracil bases replaced with gemcitabine or a 5-halouracil, respectively. More specifically, the present disclosure reveals that the replacement of cytosine nucleotides within a microRNA nucleotide sequence with a gemcitabine molecule increases the ability of the microRNA to inhibit cancer progression and tumorigenesis. In addition, the present disclosure reveals that the replacement of cytosine nucleotides within a microRNA nucleotide sequence with a gemcitabine molecule and replacement of uracil bases with 5-halouracil increases the ability of the microRNA to inhibit cancer development. As such, the present disclosure provides various modified nucleic acid (e.g., microRNA) compositions having gemcitabine molecules incorporated in their nucleic acid sequences and methods for using the same.
    Type: Application
    Filed: March 13, 2020
    Publication date: May 12, 2022
    Applicant: The Research Foundation for The State University of New York
    Inventors: Jingfang JU, Andrew FESLER
  • Publication number: 20220090076
    Abstract: The present disclosure provides nucleic acid compositions that incorporate one or more halouracil molecules. More specifically, the present disclosure reveals that the replacement of uracil nucleotides within a microRNA nucleotide sequence with a 5-halouracil increases the ability of the micro-RNA to inhibit cancer progression and tumorigenesis. As such, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-halouracil molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.
    Type: Application
    Filed: November 24, 2021
    Publication date: March 24, 2022
    Applicant: The Research Foundation for The State University of New York
    Inventors: Jingfang Ju, Andrew Fesler, Younghwa Song, Jun Chung
  • Patent number: 11236337
    Abstract: The present disclosure provides nucleic acid compositions that incorporate one or more halouracil molecules. More specifically, the present disclosure reveals that the replacement of uracil nucleotides within a microRNA nucleotide sequence with a 5-halouracil increases the ability of the micro-RNA to inhibit cancer progression and tumorigenesis. As such, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-halouracil molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: February 1, 2022
    Assignee: The Research Foundation for The State University of New York
    Inventors: Jingfang Ju, Andrew Fesler, Younghwa Song, Jun Chung
  • Publication number: 20200354719
    Abstract: The present disclosure provides nucleic acid compositions that incorporate one or more halouracil molecules. More specifically, the present disclosure reveals that the replacement of uracil nucleotides within a microRNA nucleotide sequence with a 5-halouracil increases the ability of the micro-RNA to inhibit cancer progression and tumorigenesis. As such, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-halouracil molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.
    Type: Application
    Filed: June 26, 2020
    Publication date: November 12, 2020
    Applicant: The Research Foundation for The State University of New York
    Inventors: Jingfang Ju, Andrew Fesler, Younghwa Song, Jun Chung
  • Patent number: 10697020
    Abstract: The current disclosure describes methods for identifying subjects that would benefit from treatment with a chemotherapeutic agent. The disclosure is based in part on the observation that miR-129 expression levels are reduced in colorectal cancer. Accordingly, the current disclosure provides therapeutic compositions and methods for altering the expression of a miR-129 effector. Described herein are methods for characterizing the stage of colorectal cancer in a subject, based on the levels of miR-129 expression. The disclosure also identifies miR-129 as a predictive biomarker for cancer diagnosis and the subsequent treatment with directed therapeutic agents including but not limited to miR-129 nucleic acid molecules and/or a chemotherapeutic agent. The current disclosure also identifies novel therapeutic agents that modulate the level of BCL2, TS and/or E2F3 expression, as well as sensitize a subject to treatment with a chemotherapeutic agent.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: June 30, 2020
    Assignee: The Research Foundation for The State University of New York
    Inventors: Jingfang Ju, Mihriban Karaayvaz, Haiyan Zhai
  • Publication number: 20190062754
    Abstract: The present disclosure provides nucleic acid compositions that incorporate one or more halouracil molecules. More specifically, the present disclosure reveals that the replacement of uracil nucleotides within a microRNA nucleotide sequence with a 5-halouracil increases the ability of the micro-RNA to inhibit cancer progression and tumorigenesis. As such, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-halouracil molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.
    Type: Application
    Filed: October 31, 2018
    Publication date: February 28, 2019
    Applicant: The Research Foundation for The State University of New York
    Inventors: Jingfang Ju, Andrew Fesler
  • Publication number: 20160090636
    Abstract: The current disclosure describes methods for identifying subjects that would benefit from treatment with a chemotherapeutic agent. The disclosure is based in part on the observation that miR-129 expression levels are reduced in colorectal cancer. Accordingly, the current disclosure provides therapeutic compositions and methods for altering the expression of a miR-129 effector. Described herein are methods for characterizing the stage of colorectal cancer in a subject, based on the levels of miR-129 expression. The disclosure also identifies miR-129 as a predictive biomarker for cancer diagnosis and the subsequent treatment with directed therapeutic agents including but not limited to miR-129 nucleic acid molecules and/or a chemotherapeutic agent. The current disclosure also identifies novel therapeutic agents that modulate the level of BCL2, TS and/or E2F3 expression, as well as sensitize a subject to treatment with a chemotherapeutic agent.
    Type: Application
    Filed: May 14, 2014
    Publication date: March 31, 2016
    Applicant: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Jingfang JU, Mihriban KARAAYVAZ, Haiyan ZHAI
  • Publication number: 20160024597
    Abstract: Methods for modulating expression of a component of a cell, comprising contacting the cell with a nucleic acid comprising an miR-140 nucleic acid sequence in an amount sufficient to modulate the cellular component are provided. Overexpression of miR-140 inhibits cell proliferation in both U-2 OS (wt-p53) and HCT 116 (wt-p53) cell lines. Cells transfected with miR-140 are more resistant to chemotherapeutic agent methotrexate. mi-140 expression is related to HDAC4 protein expression. The claimed methods reduce the protein expression level of HDAC4 without degrading the target mRNA.
    Type: Application
    Filed: October 9, 2015
    Publication date: January 28, 2016
    Inventors: Jingfang Ju, Yuan Wang, Bo Song
  • Publication number: 20150152422
    Abstract: MicroRNAs (miRNAs) are a class of non-coding small RNA molecules that regulate gene expression at the post-transcriptional level by interacting with 3? untranslated regions (UTRs) of their target mRNAs. The invention relates to the application of miR-192 and miR-215. Both of these miRNAs impact cellular proliferation through the p53-miRNA circuit, and interact with dihydrofolate reductase (DHFR) and thymidylate synthase (TS). Particularly, upregulation of these miRNAs reduces cellular proliferation. The invention relates to this discovery. For example, inhibiting miR-192 and/or miR-215 sensitizes a neoplasm or a subject with a neoplasm to chemotherapeutic agents. Furthermore, measuring the levels of miR-192 and/or miR-215 provides one with information regarding whether the neoplasm or subject will respond to chemotherapeutic agents. Accordingly, the invention relates to composition and methods relating to the identification, characterization and modulation of the expression of miR-192 and miR-215.
    Type: Application
    Filed: November 26, 2014
    Publication date: June 4, 2015
    Inventors: Jingfang Ju, Bo Song, Yuan Wang
  • Patent number: 8927207
    Abstract: MicroRNAs (miRNAs) are a class of non-coding small RNA molecules that regulate gene expression at the post-transcriptional level by interacting with 3? untranslated regions (UTRs) of their target mRNAs. The invention relates to the application of miR-192 and miR-215. Both of these miRNAs impact cellular proliferation through the p53-miRNA circuit, and interact with dihydrofolate reductase (DHFR) and thymidylate synthase (TS). Particularly, upregulation of these miRNAs reduces cellular proliferation. The invention relates to this discovery. For example, inhibiting miR-192 and/or miR-215 sensitizes a neoplasm or a subject with a neoplasm to chemotherapeutic agents. Furthermore, measuring the levels of miR-192 and/or miR-215 provides one with information regarding whether the neoplasm or subject will respond to chemotherapeutic agents. Accordingly, the invention relates to composition and methods relating to the identification, characterization and modulation of the expression of miR-192 and miR-215.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: January 6, 2015
    Assignee: Research Foundation of State University of New York
    Inventors: Jingfang Ju, Bo Song, Yuan Wang
  • Patent number: 8343719
    Abstract: The present invention relates to the discovery of certain microRNAs that correlate with certain information regarding cancer. The microRNAs of the invention are selected from the group consisting of hsa-miR-15b, hsa-miR-181b, hsa-miR-191, hsa-miR-200c, and hsa-let-7g. If the expression of these microRNAs is increase, then the increased expression of these microRNAs is diagnostic for cancer, characterizes the cancer, prognosticates an expected response to cancer treatments, and/or prognosticates an expected survival of a patient. Embodiments of this discovery include a method, composition, kit and isolated nucleic acid.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: January 1, 2013
    Assignee: Research Foundation of State University of New York
    Inventors: Jingfang Ju, Yaguang Xi, Nakajima Go
  • Publication number: 20120087992
    Abstract: Methods for modulating expression of a component of a cell, comprising contacting the cell with a nucleic acid comprising an miR-140 nucleic acid sequence in an amount sufficient to modulate the cellular component are provided. Overexpression of miR-140 inhibits cell proliferation in both U-2 OS (wt-p53) and HCT 116 (wt-p53) cell lines. Cells transfected with miR-140 are more resistant to chemotherapeutic agent methotrexate, mi-140 expression is related to HDAC4 protein expression. The claimed methods reduce the protein expression level of HDAC4 without degrading the target mRNA.
    Type: Application
    Filed: March 22, 2010
    Publication date: April 12, 2012
    Inventors: Jingfang Ju, Yuan Wang, Bo Song
  • Publication number: 20110166201
    Abstract: MicroRNAs (miRNAs) are a class of non-coding small RNA molecules that regulate gene expression at the post-transcriptional level by interacting with 3? untranslated regions (UTRs) of their target mRNAs. The invention relates to the application of miR-192 and miR-215. Both of these miRNAs impact cellular proliferation through the p53-miRNA circuit, and interact with dihydrofolate reductase (DHFR) and thymidylate synthase (TS). Particularly, upregulation of these miRNAs reduces cellular proliferation. The invention relates to this discovery. For example, inhibiting miR-192 and/or miR-215 sensitizes a neoplasm or a subject with a neoplasm to chemotherapeutic agents. Furthermore, measuring the levels of miR-192 and/or miR-215 provides one with information regarding whether the neoplasm or subject will respond to chemotherapeutic agents. Accordingly, the invention relates to composition and methods relating to the identification, characterization and modulation of the expression of miR-192 and miR-215.
    Type: Application
    Filed: June 5, 2009
    Publication date: July 7, 2011
    Inventors: Jingfang Ju, Bo Song, Yuan Wang
  • Publication number: 20100203513
    Abstract: The present invention relates to the discovery of certain microRNAs that correlate with certain information regarding cancer. The microRNAs of the invention are selected from the group consisting of hsa-miR-15b, hsa-miR-181b, hsa-miR-191, hsa-miR-200c, and hsa-let-7g. If the expression of these microRNAs is increase, then the increased expression of these microRNAs is diagnostic for cancer, characterizes the cancer, prognosticates an expected response to cancer treatments, and/or prognosticates an expected survival of a patient. Embodiments of this discovery include a method, composition, kit and isolated nucleic acid.
    Type: Application
    Filed: October 30, 2007
    Publication date: August 12, 2010
    Applicant: RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
    Inventors: Jingfang Ju, Yaguang Xi, Nakajima Go
  • Publication number: 20070178452
    Abstract: Disclosed is a method in which DNA sequences derived from microsome-associated mRNA sequences in a mixed sample or in an arrayed single sequence clone can be determined and classified without sequencing. The methods make use of information on the presence of carefully chosen target subsequences, typically of length from 4 to 8 base pairs, and preferably the length between target subsequences in a sample DNA sequence together with DNA sequence databases containing lists of sequences likely to be present in the sample to determine a sample sequence. The preferred method uses restriction endonucleases to recognize target subsequences and cut the sample sequence. Then carefully chosen recognition moieties are ligated to the cut fragments, the fragments amplified, and the experimental observation made. Polymerase chain reaction (PCR) is the preferred method of amplification.
    Type: Application
    Filed: October 21, 2002
    Publication date: August 2, 2007
    Inventors: Pascal Bouffard, John Herrmann, Chunli Huang, Michael Jeffers, Jingfang Ju, Luca Rastelli, Juliette Shimkets, Jan Simons, Bruce Taillon
  • Publication number: 20040038223
    Abstract: The present invention provides novel isolated polynucleotides and small molecule target polypeptides encoded by the polynucleotides. Antibodies that immunospecifically bind to a novel small molecule target polypeptide or any derivative, variant, mutant or fragment of that polypeptide, polynucleotide or antibody are disclosed, as are methods in which the small molecule target polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states. More specifically, the present invention discloses methods of using recombinantly expressed and/or endogenously expressed proteins in various screening procedures for the purpose of identifying therapeutic antibodies and therapeutic small molecules associated with diseases. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
    Type: Application
    Filed: October 1, 2002
    Publication date: February 26, 2004
    Inventors: Glennda Smithson, Isabelle Millet, John A. Peyman, Ramesh Kekuda, Jingfang Ju, Li Li, Xiaojia (Sasha) Guo, Meera Patturajan, Kimberly A. Spytek, Shlomit R. Edinger, Karen Ellerman, Uriel M. Malyankar, Tatiana Ort, Linda Gorman, Bryan D. Zerhusen, David W. Anderson, Mei Zhong, Elina Catterton, Weizhen Ji, Charles E. Miller, Luca Rastelli, David J. Stone, Carol E. A. Pena, Suresh G. Shenoy, Richard A. Shimkets, Mark E. Rothenberg, Martin D. Leach, Michele L. Agee, Constance Berghs, Vincent A. DiPippo, Andrew Eisen, Esha A. Gangolli, Daniel K. Rieger, Steven K. Spaderna
  • Publication number: 20030185815
    Abstract: Disclosed herein are nucleic acid sequences that encode polypeptides. Also disclosed are antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids, polypeptides, or antibodies, or fragments thereof.
    Type: Application
    Filed: April 2, 2002
    Publication date: October 2, 2003
    Inventors: Muralidhara Padigaru, Suresh G. Shenoy, Ramesh Kekuda, Luca Rastelli, Peter D. Mezes, Glennda Smithson, Xiaojia Guo, Valerie Gerlach, Stacie J. Casman, Ferenc L. Boldog, Li Li, Bryan D. Zerhusen, Velizar T. Tchernev, Esha A. Gangolli, Corine A. M. Vernet, Kimberly A. Spytek, Uriel M. Malyankar, Meera Patturajan, Charles E. Miller, Raymond J. Taupier, Melvyn P. Heyes, Jingfang Ju, John A. Peyman, Elina Catterton, John R. MacDougall, Shlomit R. Edinger, David J. Stone, Ann Mazur
  • Publication number: 20030176385
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of H-Ras, WNT-7B, acetylglucosaminyltransferase, voltage-gated K channel, IL-8, ion transport, Map3K8 and Thymidine kinase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding H-Ras, WNT-7B, acetylglucosaminyltransferase, voltage-gated K channel, IL-8, ion transport, Map3K8 and Thymidine kinase. Methods of using these compounds for modulation of H-Ras, WNT-7B, acetylglucosaminyltransferase, voltage-gated K channel, IL-8, ion transport, Map3K8 and Thymidine kinase.expression and for treatment of diseases associated with expression of H-Ras, WNT-7B, acetylglucosaminyltransferase, voltage-gated K channel, 1L-8, ion transport, Map3KS and Thymidine kinase are provided.
    Type: Application
    Filed: November 27, 2002
    Publication date: September 18, 2003
    Inventors: Jingfang Ju, Chunli Huang, Haihong Zhong, Jan Fredrik Simons, Bruce E. Taillon, John S. Chant, John A. Peyman, Glennda Smithson, Isabelle Millet
  • Publication number: 20020061526
    Abstract: Disclosed is a method in which DNA sequences derived from polysome-associated mRNA sequences in a mixed sample or in an arrayed single sequence clone can be determined and classified without sequencing. The methods make use of information on the presence of carefully chosen target subsequences, typically of length from 4 to 8 base pairs, and preferably the length between target subsequences in a sample DNA sequence together with DNA sequence databases containing lists of sequences likely to be present in the sample to determine a sample sequence. The preferred method uses restriction endonucleases to recognize target subsequences and cut the sample sequence. Then carefully chosen recognition moieties are ligated to the cut fragments, the fragments amplified, and the experimental observation made. Polymerase chain reaction (PCR) is the preferred method of amplification.
    Type: Application
    Filed: May 21, 2001
    Publication date: May 23, 2002
    Inventors: Jingfang Ju, Jan Fredrik Simons